Drug intelligence / Profile preview

adenovirus vaccine

Development stage: Approved
Modality: Vaccines & Immunotherapeutics
Administration: Oral, Subcutaneous, Intratracheal, Conjunctival, In Ovo, Intranasal, Intramuscular

Overview

The adenovirus vaccine is an approved pharmaceutical drug designed to combat the spread of infectious respiratory disease caused by adenovirus types 4 and 7. It has been supplied to U.S. military personnel, particularly in basic training camps, as a preventive healthcare measure. Barr Laboratories, a subsidiary of Teva, and subsequently Teva Pharmaceuticals, have been key manufacturers and suppliers of this vaccine under contracts with the U.S. Department of Defense.

Other names: 腺病毒疫苗

Targets

CXADR (Coxsackievirus and adenovirus receptor)CD46 (CD46 Molecule)αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on adenovirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adenovirus vaccine.

Explore the full profile